首页> 外文OA文献 >Application of Hepatic Venous Pressure Gradient to Predict Prognosis in Cirrhotic Patients with a Low Model for End-stage Liver Disease Score
【2h】

Application of Hepatic Venous Pressure Gradient to Predict Prognosis in Cirrhotic Patients with a Low Model for End-stage Liver Disease Score

机译:肝静脉压梯度在肝硬化患者中预测肝硬化患者终末期肝病分数的预后

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

: Background/aim: We aimed to derive a model representing the dynamic status of cirrhosis and to discriminate patients with poor prognosis even if the Model for End-Stage Liver Disease (MELD) score is low. Methods: This study retrospectively enrolled 700 cirrhotic patients with a MELD score of less than 20 who underwent hepatic venous pressure gradient (HVPG) measurement. A model named H6C score (= HVPG + 6 × CTP score) to predict overall survival was derived and internal and external validations were conducted with the derivation and validation cohorts. Results: The H6C score using the HVPG was developed based on a multivariate Cox regression analysis. The H6C score showed a great predictive power for overall survival with a time-dependent AUC of 0.733, which was superior to that of a MELD of 0.602. In patients with viral etiology, the performance of the H6C score was much improved with a time-dependent AUC of 0.850 and was consistently superior to that of the MELD (0.748). Patients with an H6C score below 45 demonstrated an excellent overall survival with a 5-year survival rate of 91.5%. Whereas, patients with an H6C score above 64 showed a dismal prognosis with a 5-year survival rate of 51.1%. The performance of the H6C score was further verified to be excellent in the validation cohort. Conclusion: This new model using the HVPG provides an excellent predictive power in cirrhotic patients, especially with viral etiology. In patients with H6C above 64, it would be wise to consider early liver transplantation to positively impact long-term survival, even when the MELD score is low.
机译::背景/目的:我们旨在推导出一种代表肝硬化动态状态的模型,并使终级肝病(MELD)评分的模型降低了预后的患者。方法:本研究回顾性地注册了700名肝硬化患者,其融合得分小于20岁的肝静脉压梯度(HVPG)测量。推导出一种名为H6C评分(= HVPG + 6×CTP评分)的模型,并通过推导和验证队列进行内部和外部验证。结果:使用HVPG的H6C分数是基于多元COX回归分析开发的。 H6C评分显示出总存活的良好预测力,其依赖于0.733,其优于0.602的含量。在病毒病毒学患者中,H6C评分的性能大大提高了0.850的时间依赖性AUC,并且始终如一地优于融合(0.748)。 H6C得分低于45的患者表现出优异的整体生存率,5年生存率为91.5%。虽然64升H6C得分的患者显示出令人沮丧的预后,5年生存率为51.1%。在验证队列中进一步验证了H6C得分的性能。结论:使用HVPG的新模型在肝硬化患者中提供了出色的预测力,尤其是病毒性病因。在64℃以上的H6C患者中,考虑早期肝移植以积极影响长期存活,即使在融合得分低时也是明智的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号